Last reviewed · How we verify
morphine sulfate extended release capsules
Morphine sulfate extended release capsules, marketed by Pfizer, hold a significant position in the pain management segment. A key strength lies in the extended patent protection until 2028, which helps maintain market exclusivity. The primary risk is the intense competition from other pain management drugs, which could erode market share.
At a glance
| Generic name | morphine sulfate extended release capsules |
|---|---|
| Also known as | AVINZA, Treatment A, Test product |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Two Multimodal Analgesia Regimens in Total Knee Arthroplasty (NA)
- Effect of Combined Morphine and Duloxetine on Chronic Pain (PHASE4)
- To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules (PHASE1)
- Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment (PHASE1)
- Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment (PHASE1)
- A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER) (PHASE1)
- Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)
- Breathlessness Exertion and Morphine Sulphate (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |